 <h1>Dabigatran Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to dabigatran: oral capsule</i></p><h3>Warning</h3><p class="blackboxWarning-title">Oral route (Capsule)</p><p>Premature discontinuation of dabigatran etexilate mesylate increases the risk of thrombotic events. If anticoagulation with dabigatran etexilate mesylate must be discontinued for other than pathological bleeding, consider another anticoagulant. Epidural or spinal hematomas may occur with dabigatran etexilate mesylate therapy in patients undergoing neuraxial anesthesia or spinal puncture. Monitor patients for neurological impairment and treat urgently.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, dabigatran may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking dabigatran:</p><p>
<i>More common</i>
</p><ul>
<li>Acid or sour stomach</li>
<li>belching</li>
<li>black, tarry stools</li>
<li>bloody stools</li>
<li>constipation</li>
<li>diarrhea</li>
<li>heartburn</li>
<li>indigestion</li>
<li>nausea</li>
<li>pain or burning in the throat</li>
<li>stomach discomfort, upset, burning, or pain</li>
<li>vomiting</li>
<li>vomiting of blood or material that looks like coffee grounds</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Chest pain or discomfort</li>
<li>cough</li>
<li>difficulty with swallowing</li>
<li>dizziness</li>
<li>fainting or loss of consciousness</li>
<li>fast or irregular breathing</li>
<li>pain or discomfort in the arms, jaw, back or neck</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>redness of the skin</li>
<li>skin rash, hives, welts, or itching skin</li>
<li>sweating</li>
<li>tightness in the chest</li>
<li>trouble breathing</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Bleeding gums</li>
<li>blood in the urine</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs</li>
<li>pinpoint red spots on the skin</li>
<li>unusual bleeding or bruising</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of dabigatran may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Incidence not known</i>
</p><ul>
<li>Hair loss or thinning of the hair</li>
</ul><p>
<!-- end oral capsule --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to dabigatran: oral capsule</i></p><h3>General</h3><p>Bleeding is the most serious side effect reported with dabigatran.  Major or severe bleeding may occur and, regardless of location, may lead to disabling, life-threatening or even fatal outcomes.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Major bleeds have occurred in critical areas or organs such as, intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal, intra-articular, or pericardial.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Bleeding up to 16.5%</p>
<p><b>Uncommon</b> (0.1% to 1%): Hematoma, hemorrhage<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Dyspepsia: upper abdominal pain, abdominal discomfort, epigastric discomfort; gastritis like symptoms, esophagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis, and gastrointestinal ulcer</p>
<p><b>Common</b> (1% to 10%): Diarrhea, nausea</p>
<p><b>Uncommon</b> (0.1% to 1%): rectal hemorrhage, hemorrhoidal hemorrhage, vomiting, dysphagia</p>
<p><b>Postmarketing reports</b>: Esophageal ulcer<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Skin hemorrhage</p>
<p><b>Postmarketing reports</b>: Angioedema, alopecia<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Anemia</p>
<p><b>Uncommon</b> (0.1% to 1%): Hemoglobin decreased, thrombocytopenia, occult blood positive</p>
<p><b>Rare</b> (less than 0.1%): Hematocrit decreased </p>
<p><b>Postmarketing reports</b>: Agranulocytosis, neutropenia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Wound secretion (5%)</p>
<p><b>Rare</b> (less than 0.1%): Traumatic hemorrhage<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Urogenital hemorrhage (including hematuria 1.2%) </p>
<p><b>Uncommon</b> (0.1% to 1%): Positive blood urine tests<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Epistaxis (0.6% to 0.7%)</p>
<p><b>Uncommon</b> (0.1% to 1%): Hemoptysis<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Uncommon</b> (0.1% to 1%): Abnormal hepatic function/liver function test, ALT increased, AST increased, hepatic enzyme increased</p>
<p><b>Rare</b> (less than 0.1%): Hyperbilirubinemia, transaminases increased<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Urticaria, rash, pruritus, allergic edema, anaphylactic reaction, anaphylactic shock</p>
<p><b>Frequency not reported</b>: Bronchospasm<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Uncommon</b> (0.1% to 1%): Hemarthrosis<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Uncommon</b> (0.1% to 1%): Intracranial hemorrhage</p>
<p><b>Frequency not reported</b>: Intracerebral hemorrhage (Hemorrhagic stroke), subarachnoid and subdural bleeds<sup>[Ref]</sup></p><h3>Local</h3><p><b>Rare</b> (less than 0.1%): Injection site hemorrhage, catheter site hemorrhage, incision site hemorrhage<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. "Product Information. Pradaxa (dabigatran)." Boehringer-Ingelheim, Ridgefield, CT. </p><p id="ref_4">4. To K,  Reynolds C,  Spinler SA "Rash associated with dabigatran etexilate." Pharmacotherapy 33 (2013): e23-7</p></div>
<div class="more-resources" id="moreResources">
<h2>More about dabigatran</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Imprints, Shape &amp; Color Data</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>91 Reviews</li>
<li>Drug class: thrombin inhibitors</li>
<li>FDA Alerts (4)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Dabigatran &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Pradaxa</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Deep Vein Thrombosis/Pulmonary Embolism Prophylaxis Following Hip Replacement Surgery</li>
<li>Prevention of Thromboembolism in Atrial Fibrillation</li>
<li>Deep Vein Thrombosis</li>
<li>Pulmonary Embolism</li>
<li>Deep Vein Thrombosis, Prophylaxis</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to dabigatran: oral capsule</i></p><h3>General</h3><p>Bleeding is the most serious side effect reported with dabigatran.  Major or severe bleeding may occur and, regardless of location, may lead to disabling, life-threatening or even fatal outcomes.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Major bleeds have occurred in critical areas or organs such as, intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal, intra-articular, or pericardial.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Bleeding up to 16.5%</p><p><b>Uncommon</b> (0.1% to 1%): Hematoma, hemorrhage<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Dyspepsia: upper abdominal pain, abdominal discomfort, epigastric discomfort; gastritis like symptoms, esophagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis, and gastrointestinal ulcer</p><p><b>Common</b> (1% to 10%): Diarrhea, nausea</p><p><b>Uncommon</b> (0.1% to 1%): rectal hemorrhage, hemorrhoidal hemorrhage, vomiting, dysphagia</p><p><b>Postmarketing reports</b>: Esophageal ulcer<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Skin hemorrhage</p><p><b>Postmarketing reports</b>: Angioedema, alopecia<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Anemia</p><p><b>Uncommon</b> (0.1% to 1%): Hemoglobin decreased, thrombocytopenia, occult blood positive</p><p><b>Rare</b> (less than 0.1%): Hematocrit decreased </p><p><b>Postmarketing reports</b>: Agranulocytosis, neutropenia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Wound secretion (5%)</p><p><b>Rare</b> (less than 0.1%): Traumatic hemorrhage<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Urogenital hemorrhage (including hematuria 1.2%) </p><p><b>Uncommon</b> (0.1% to 1%): Positive blood urine tests<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Epistaxis (0.6% to 0.7%)</p><p><b>Uncommon</b> (0.1% to 1%): Hemoptysis<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Uncommon</b> (0.1% to 1%): Abnormal hepatic function/liver function test, ALT increased, AST increased, hepatic enzyme increased</p><p><b>Rare</b> (less than 0.1%): Hyperbilirubinemia, transaminases increased<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Urticaria, rash, pruritus, allergic edema, anaphylactic reaction, anaphylactic shock</p><p><b>Frequency not reported</b>: Bronchospasm<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Uncommon</b> (0.1% to 1%): Hemarthrosis<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Uncommon</b> (0.1% to 1%): Intracranial hemorrhage</p><p><b>Frequency not reported</b>: Intracerebral hemorrhage (Hemorrhagic stroke), subarachnoid and subdural bleeds<sup>[Ref]</sup></p><h3>Local</h3><p><b>Rare</b> (less than 0.1%): Injection site hemorrhage, catheter site hemorrhage, incision site hemorrhage<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. "Product Information. Pradaxa (dabigatran)." Boehringer-Ingelheim, Ridgefield, CT. </p><p id="ref_4">4. To K,  Reynolds C,  Spinler SA "Rash associated with dabigatran etexilate." Pharmacotherapy 33 (2013): e23-7</p><h2>More about dabigatran</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Imprints, Shape &amp; Color Data</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>91 Reviews</li>
<li>Drug class: thrombin inhibitors</li>
<li>FDA Alerts (4)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Dabigatran &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Deep Vein Thrombosis/Pulmonary Embolism Prophylaxis Following Hip Replacement Surgery</li>
<li>Prevention of Thromboembolism in Atrial Fibrillation</li>
<li>Deep Vein Thrombosis</li>
<li>Pulmonary Embolism</li>
<li>Deep Vein Thrombosis, Prophylaxis</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>